Background The Xpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA) can detect tuberculosis and its multidrugresistant form with very high sensitivity and specifi city in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries. We aimed to assess operational feasibility, accuracy, and eff ectiveness of implementation in such settings.
Introduction
Two of the three key infectious diseases of man, HIV and malaria, can be diagnosed in primary-care settings with straightforward rapid tests. No such technology has been available to accurately detect tuberculosis and its drugresistant forms, and this absence has been a major obstacle to improvement of tuberculosis care and reduction of the global burden of disease. Microscopy alone, although inexpensive, misses many patients and detects only those with relatively advanced disease. [1] [2] [3] Presently, only 28% of expected incident cases of tuberculosis are detected and reported as smear positive. 4 Undetected cases of disease increase morbidity, mortality, and disease transmission. [5] [6] [7] In many countries, epidemic HIV infection has further reduced the sensitivity of microscopy and increased the necessity of rapid diagnosis of tuberculosis. The mortality of untreated or mistreated tuberculosis in people with advanced HIV is high. [8] [9] [10] Autopsy studies in various countries have shown that 30-60% of people with HIV infection may die with tuberculosis, often undiagnosed, moving the cure-rate target of 85% for tuberculosis out of reach unless available diagnostic technologies can be improved. 11, 12 Multidrug-resistant tuberculosis is an increasing concern globally and directly threatens disease-control eff orts in many countries. 13 Only 30 000 of nearly 500 000 new cases of multidrug-resistant tuberculosis every year 13 are detected and reported, 4 and misdiagnosis causes thousands of deaths, nosocomial and community transmission, and amplifi cation of drug resistance. [14] [15] [16] In recognition of these issues, substantial eff orts are being made to strengthen laboratory capacity to diagnose smear-negative and multidrug-resistant tuberculosis, including increased use of solid and liquid culture, conventional drug-susceptibility testing, and line-probe assays. Unfortunately, these tests require extensive laboratory infrastructure and cannot be done outside of reference facilities.
Recently, a real-time PCR assay for Mycobacterium tuberculosis that simultaneously detects rifampicin resistance was developed on the GeneXpert platform (Cepheid, Sunnyvale, CA, USA), which integrates sample processing and greatly simplifi es testing. 17, 18 This assay, Xpert MTB/RIF, showed excellent performance in a multicentre study 19 undertaken in reference laboratories. In the study, 19 one-off direct MTB/RIF testing detected 92·2% of cases of pulmonary tuberculosis, including 72·5% of those with smear-negative disease, which was equivalent to that reported for solid culture.
Diagnostic tests often do well in initial studies that are usually done in near-ideal settings in reference laboratories; however, performance is frequently reduced when assays are tested in settings of intended use. In our study, we aimed to establish whether the MTB/RIF test was robust enough to retain high accuracy when used in district and subdistrict health facilities in resource-poor countries, and to measure the operational feasibility and eff ectiveness of its implementation in such settings.
Methods

Study population
In our multicentre implementation study, we enrolled adults aged 18 years or older with at least 2 weeks of cough who presented consecutively to urban or periurban primary-care health centres in South Africa, Peru, and India, to drug-resistance screening facilities in Azerbaijan and the Philippines, and to an emergency room at a central hospital in Uganda, and provided at least two sputum samples. Patients were excluded from the main analyses if their second sputum sample was collected more than 1 week after the fi rst sample, if no culture was done, or if there was no valid culture, no valid MTB/RIF test result, smear-positive with no positive cultures, only one positive culture with 20 or fewer colonies for solid culture or more than 28 days to positivity for liquid culture, a positive culture during follow-up only, only one positive culture with missing speciation result, a positive culture with only nontuberculous mycobacterial growth, or discrepant rifampicin results by conventional drug-susceptibility testing on two samples.
We established the MTB/RIF test in the microscopy area of nine laboratories that were located within the same building at eight sites or a nearby building at one site (in one of two sites in Cape Town, South Africa). We chose study sites to represent diverse populations of patients and laboratory capacities. Sites in South Africa and Uganda served populations with a high prevalence of HIV, centres in Peru and India served populations with low prevalence of HIV and multidrug-resistant tuberculosis, and sites in Azerbaijan and the Philippines served populations with a high prevalence of multidrugresistant tuberculosis.
The study was endorsed by national tuberculosis programmes of participating countries and approved by nine governing institutional review boards. The requirement to obtain individual informed consent was waived by all institutional review boards. 
Procedures
Our study was divided into two phases. In the validation phase, MTB/RIF test results were not reported or used for management of patients. This phase allowed the collection of baseline data and confi rmed that the site could accurately undertake the MTB/RIF test. In the implementation phase, MTB/RIF test results informed tuberculosis treatment decisions. Before sites could move to the implementation phase they were required to meet predefi ned performance targets, which were reviewed and approved by the institutional review boards. Table 1 shows the laboratory procedures used in every country. In both phases, participants provided 2-3 sputum samples as per local routine. One sample underwent smear microscopy and direct MTB/RIF testing, the second underwent smear microscopy, culture, and drug-susceptibility testing. The third sample was only collected at sites that routinely required three microscopy results for management of patients.
In South Africa, the routine use of bleach-pretreatment for fl uorescent microscopy meant that MTB/RIF testing on the same sputum sample was not possible. Therefore, in South Africa we used a study design with weekly alternation between a baseline group and implementation group. In the baseline group, routine smear microscopy from a bleach-treated pellet was done, which was replaced by the MTB/RIF test (used for management of patients) in the implementation group. In both groups, a second specimen was obtained for smear microscopy from a sodium hydroxide (NaOH)-treated pellet, culture, and drug-susceptibility testing.
The MTB/RIF test was done on raw sputum samples with an automated readout provided to the user as described elsewhere. 18 GeneXpert four-module devices were placed on an open bench in the microscopy area. On the basis of biosafety data, 17 the MTB/RIF test sample preparation step was done applying the same local RIF=rifampicin. MDR=multidrug resistant. DST=drug-susceptibility testing. *Some patients met several exclusion criteria and are listed more than once. †In South Africa only. ‡680 suspected cases of MDR tuberculosis were not included in the case-detection analysis to avoid patient-selection bias (patients were expected to have a higher tuberculosis prevalence and supposedly higher bacillary load); a subgroup analysis for these patients is shown in webappendix p 3. 
Characteristics of study population AC=air conditioning. *For 0·1% of enrolled patients, whether they were part of the validation or implementation phase was not reported. †Estimation based on epidemiological studies or surveys. ‡For calculations of prevalence of tuberculosis and rifampicin resistance, the exclusion criteria described in the methods section have been applied. §Calculations of rifampicin resistance prevalence were done only on the basis of patients who had rifampicin sensitivity testing. 20 All positive cultures underwent MPT64-based (Capilia tuberculosis assay; Tauns, Numazu, Japan) species confi rmation 21 and, if positive for M tuberculosis, conventional drugsusceptibility testing with Löwenstein-Jensen proportion or mycobacteria growth indicator tube (MGIT). In South Africa, the line-probe assay MTBDRplus (Hain Lifescience, Nehren, Germany) was done on NaOHtreated pellets for smear-positive sputum and on culture isolates for smear-negative sputum. Conventional drugsusceptibility testing was then used for specimens testing positive for drug-resistance-associated mutations. In Uganda, line-probe assay and, for 10% of culture positive patients (every tenth patient), Löwenstein-Jensen proportion was performed on MGIT isolates (except when only positive on Löwenstein-Jensen). HIV results were obtained from clinical records.
Clinicians categorised participants into two groups: patients who had suspected tuberculosis and presented for case detection and patients with suspected multidrugresistant tuberculosis who presented for resistance detection (patients who received tuberculosis treatment within the past year or had contact with multidrug-resistant tuberculosis). For analysis, patients with suspected tuberculosis were divided into four categories: smearpositive and culture-positive pulmonary tuber culosis; smear-negative and culture-positive pulmonary tuberculosis; smear-negative, culture-negative and not treated (non-tuberculosis); and smear-negative and culturenegative but treated for tuberculosis on the basis of clinical and radiological fi ndings (clinical tuberculosis). A patient was regarded as having smear-positive tuber culosis on the basis of at least two scanty smears (1-9 bacilli per 100 fi elds [1000× for light microscopy and 400× for fl uorescence microscopy]) or one or more smears of grade 1+ or higher (10-99 bacilli per 100 fi elds). A culture-positive case was defi ned as the isolation of M tuberculosis in at least one culture. Patients who were culture-positive (suspected tuberculosis and multidrug-resistant tuberculosis) were categorised as sensitive or resistant to rifampicin.
Statistical analysis
We calculated sensitivity and specifi city of the MTB/RIF test for each patient category stratifi ed by HIV and smear microscopy status, and used the results of all microscopy and culture examinations to classify patients into the four groups. To prevent selection bias, patients with suspected multidrug-resistant tuberculosis were only included in the analysis of MTB/RIF test rifampicindetection endpoints.
We quantitatively assessed operational feasibility of introduction of the MTB/RIF test by examining indicators of robustness such as indeterminate rate, frequency of DNA contamination events, and variation of performance in time and between sites. We used a hands-on and question-based profi ciency test and user-appraisal questionnaire to qualitatively establish the minimal training needs and ease of use. The Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland) study team did the training.
We assessed eff ectiveness of every method by examining the time to detection of tuberculosis and rifampicin resistance and the time to reporting of results to the clinics. Additionally, we compared the time to treatment initiation from fi rst sputum collection and the dropout rate (patients with confi rmed tuberculosis who had not started treatment) between validation and implementation phases.
Within sites we measured association between variables with the Pearson's χ² test and between sites we used the Cochran-Mantel-Haenszel statistic. We did within-patient analysis with McNemar's test. We did a subgroup analysis for excluded patients. All analyses were done with SAS version 9.2, and p<0·05 was regarded as signifi cant.
Role of the funding source
The FIND cosponsored the study and led study design, training, study coordination and monitoring, data analysis, and writing of the report. The other sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. than 90% of patients with positive cultures, with 99% specifi city for non-tuberculosis (table 4) . Performance was much the same during validation and implementation phases (webappendix p 2). A one-off MTB/RIF test identifi ed signifi cantly (p<0·0001) more cases of tuber culosis than did 2-3 smear microscopy examinations per patient, which detected 699 of 1041 culture-positive patients (sensitivity of 67·1%) and 3700 of 3718 patients without tuberculosis (specifi city of 99·5%). Although HIV co-infection signifi cantly decreased the sensitivity of smear microscopy (p<0·0001), the sensitivity of MTB/RIF was not signifi cantly aff ected by HIV co-infection status (p=0·0849; table 5). MTB/RIF test sensitivity and specifi city were much the same between basic health centres and sites with increased capacity both between countries (p=0·895 and p=0·097, respectively; webappendix p 2), and within countries with more than one site (webappendix p 2). Sensitivity of MTB/RIF testing for smear-negative tuberculosis varied between countries (p<0·0001). It was lower at sites that used a reference standard of solid and liquid cultures (Azerbaijan, Uganda, and the Philippines) and slightly higher at sites that tested morning sputum samples rather than spot sputum collections (Peru and India). MTB/RIF testing correctly identifi ed 242 of 250 cases of rifampicin-resistant tuberculosis (sensitivity of 96·8%) and 779 of 810 rifampicin-sensitive cases (specifi city of 96·2%). However, because of concern over false-positive results, especially for settings with a lowprevalence of multidrug-resistant disease, we changed the software cutoff defi ning drug resistance during the study on May 12, 2010. With modifi ed software defi nitions, our post-hoc analysis showed that sensitivity decreased to 94·4% and specifi city increased to 98·3% (table 6). 17 (6·8%) of 250 cases of rifampicin-resistant tuberculosis were sensitive to isoniazid.
Results
From
24 (16%) of 153 patients with clinically diagnosed tuberculosis, but negative culture had positive results on MTB/RIF testing. 20 (83%) of these 24 patients had clinical and radiological follow-up, and all 20 improved on tuberculosis treatment. For the 118 (91%) of 129 patients who tested negative on MTB/RIF but were treated for tuberculosis on the basis of a clinical diagnosis and had clinical and radiological follow-up, only 67 (57%) showed improvement (p<0·0001).
Median time to detection of tuberculosis for the MTB/ RIF test was 0 days (IQR 0-1), compared with 1 day (0-1) for smear microscopy, 30 days (23-43) for solid culture, Data are number of positive results/number tested (%, 95% CI). On the basis of the p values, the performance of the MTB/RIF test in this study did not diff er signifi cantly in patients who were HIV positive compared with those who were HIV negative or who were not tested for HIV infection, while the sensitivity of smear microscopy was signifi cantly reduced in patients who were HIV positive. MTB=Mycobacterium tuberculosis. RIF=rifampicin. *Determined by use of the Cochran-Mantel-Haenszel method comparing patients who are HIV positive with those whose statuses are HIV negative or unknown. ). Some results were lost or unreported (fi gure 3). Time between sputum collection and treatment initiation was very dependent on the testing method (fi gure 4). In the baseline group in South Africa and the validation phase at other sites (ie, when MTB/RIF test results were not used to direct therapy), patients with smear-negative, culture-positive tuberculosis started treatment after a median of 56 days (IQR 39-81). Once MTB/RIF test results were used to direct therapy, the median time-to-treatment for smear-negative tuber culosis reduced to 5 days (2-8). Rates of untreated smear-negative, culture-positive tuber culosis reduced from 39·3% (95% CI 32·6-46·6) at baseline to 14·7% (9·9-21·2) after implemen tation of the MTB/RIF test.
GeneXpert Data are number of positive results/number tested (%, 95% CI). The reference standard was phenotypic susceptibility testing in Peru, Azerbaijan, Uganda, and the Philippines and genotypic testing by line-probe assay followed by phenotypic drug-susceptibility testing for resistant cases in South Africa and Uganda. MTB=Mycobacterium tuberculosis. RIF=rifampicin. Table 6 : MTB/RIF test sensitivity and specifi city for detection of rifampicin resistance after change to software cutoff indeterminate rate reduced to less than 1% (14/5321 samples). In 1449 samples that were positive on MTB/RIF testing, 17 (1%) had indeterminate results for rifampicin resistance. These tests were not repeated. By comparison, the contamination rate was 441 (5%) of 9690 cultures, including repeated cultures from redecontaminated pellets from all countries apart from South Africa and the Philippines. Operators without previous molecular biology experience or computer skills passed profi ciency testing after 1-3 days of training on MTB/RIF tests, including three hands-on runs. A 1 day online training was successfully used at two sites (Peru and Azerbaijan). Monthly variation in MTB/RIF test performance did not diff er between sites (p sensitivity =0·52 on Cochran-Mantel-Haenszel test stratifi ed by smear status and p specifi city =0·46 on χ²).
In one of the high HIV-prevalence sites, microscopy was introduced at the same time as MTB/RIF testing. Although MTB/RIF sensitivity for culture-positive tuberculosis at this site was much the same as in other centres (85·9%; 116 of 135 cases), the sensitivity of microscopy with one smear per patient was only 17·8% (21 of 118 smears) compared with 46·6% (55 of 118 smears) with a second smear at the reference laboratory. These fi ndings support the laboratory managers' perception, expressed in user appraisal questionnaires, that MTB/RIF test performance might be less dependent on user skills, motivation, or workload than is microscopy.
We did not detect any DNA contamination events during monthly negative control runs, and test specifi city was high across sites. The four-module GeneXpert device was used for 1-24 tests a day with only two incidents needing product support (one network-card failure requiring device replacement and one module replacement). At four sites, the recorded operating temperatures exceeded the maximum recommended operating temperature (15-30°C) during more than 10% of runs. Test performance and frequency of indeterminate results did not show seasonal variation in these sites. In one case, the operating temperature exceeded 40°C and an error message appeared as described in the manual. Several sites had daily temperatures higher than the 2-28°C recommended for cartridge storage temperature; cartridges were stored centrally and distributed twice every month. All sites had power cuts, but used uninterruptible power supplies to support the device during short power cuts and one site used an inverter and serial car batteries during a longer power outage.
Discussion
The MTB/RIF test assay was designed specifi cally for use close to point-of-treatment in endemic disease settings, and is the fi rst of a new generation of diagnostic tests that have the potential to bring highly sensitive nucleic acid amplifi cation testing to peripheral sections of the health system (panel). In our large multicentre study, MTB/RIF testing in subdistrict microscopy facilities by routine staff with minimal training retained the accuracy seen in previous controlled studies that were undertaken in reference centres. 18, 19, [34] [35] [36] Previous studies of the MTB/RIF test that assessed either sputum samples or concentrated, decontaminated sputum pellets, have consistently reported test sensitivity of 72-75% in cases of smear-negative tuberculosis and 98-100% in cases of smear-positive tuberculosis. 18, 19, [34] [35] [36] One small retrospective study of 28 frozen pellets reported a sensitivity of 57% for cases of smear-negative tuberculosis. 35 In our study, a one-off direct MTB/RIF test detected tuberculosis in more than 90% of patients who were culture positive, including nearly 77% of those with negative smears. The robustness of these data suggests that the test can be used in various resource-scarce settings for case detection and for rapid decentralised screening of multidrugresistant tuberculosis. The ability to rapidly detect smearnegative tuberculosis in peripheral settings, including among patients with HIV, is a breakthrough in tuberculosis care and control. This is the fi rst study in which MTB/RIF test results have been made available to clinic staff to inform patient management, and hence the fi rst to describe the eff ect on time to detection and treatment. The short turnaround time resulted in substantially faster initiation of appropriate tuberculosis therapy, particularly for patients with smearnegative disease, and lower dropout rates. Many patients with tuberculosis drop out during the diagnostic process through failing to submit specimens for microscopy when prescribed, 37 submitting an initial specimen but not returning, 38 or not receiving or acting on positive test results. [39] [40] [41] Rapid testing, even if less sensitive than slower methods, can result in more patients being correctly treated. Overall, patient dropout with one-off MTB/RIF testing could possibly be reduced even further in routine conditions, as our analysis excluded 640 (9%) of 7288 enrolled patients who did not provide a second sample (fi gure 1). Although treatment decisions for multidrugresistant tuberculosis were not informed by MTB/RIF test results, delays in result reporting for rapid, but centralised drug-susceptibility testing (line-probe assay and MGIT drug-susceptibility testing) were substantially shortened by decentralised MTB/RIF testing, and would probably translate into reduced time-to-appropriate-treatment.
Although the sensitivity and specifi city of MTB/RIF test for detection of rifampicin resistance in this study was high (94·4% sensitivity and 98·3% specifi city), accuracy was higher in previous publications (99-100% sensitivity and 100% specifi city after discordant resolution by genotyping). 18, 19, [34] [35] [36] Assay development partners are working to further improve MTB/RIF test accuracy of detection of multidrug-resistant tuberculosis. The low positive-predictive value of MTB/RIF for rifampicin resistance detection that we noted in patients with a low pretest probability of multidrug-resistant tuberculosis might justify the need for confi rmatory testing with conventional methods in such settings.
Several issues might restrict the applicability of the MTB/RIF test at small health centres. The device requires stable electricity supply, although some centres successfully tested battery operation. Device deployment above 30°C is presently not recommended by the manufacturer and cartridges are confi rmed as stable at 2-28°C (eff orts are ongoing to increase the operating and storage temperatures). There were few device breakdowns in this study as the devices used were new, and there are no data for their extended use in dusty and humid conditions. The GeneXpert device needs calibration yearly, which requires either access to an MTB/RIF test distributor or internal capacity to replace modules as per manufacturer instructions.
In the study, MTB/RIF test cartridges were handled with the same level of biosafety as microscopy. As the MTB/RIF tuberculosis assay was designed to keep biohazards to a minimum, the risk should be substantially lower than that noted in microscopy. As published elsewhere, 17 the only specimen processing required is the addition of a sample reagent that is bactericidal and results in a 10⁷ reduction in viable March 18, 2011 , with the search terms "Xpert" or "GeneXpert" and "tuberculosis". We did not identify any systematic reviews. We identifi ed fi ve studies reporting on performance of the MTB/RIF test for detection of tuberculosis in respiratory specimens.
Interpretation
All studies that we identifi ed were done in research or referral laboratories and were small, 18, [34] [35] [36] apart from one large multicentre assessment. 19 Most included testing of previously collected archived samples. In these studies, the reported sensitivity of the MTB/RIF test for detection of smear-positive tuberculosis (98-100%) and smear-negative tuberculosis (72-75%) were consistent, apart from one small study that documented a sensitivity of 57% for smear-negative tuberculosis in 28 previously frozen sputum pellets. With regard to detection of rifampicin resistance, sensitivity and specifi city were very high in all previous studies (99-100% sensitivity and 100% specifi city after resolution of discordant cases by genotyping), although numbers of rifampicinresistant cases were small in all studies apart from multicentre assessment. Our study confi rms the sensitivity of the MTB/RIF test for smear-positive and smear-negative tuberculosis, when undertaken in routine microscopy centres, and showed reduced, but good, performance for detection of rifampicin resistance. Furthermore, we suggest the MTB/RIF test can provide a substantially reduced time to detection and treatment for smear-negative tuberculosis. mycobacteria in the fi rst 15 min. Additionally, unlike smear microscopy, the manual pipetting steps and the automated portion of the assay do not generate viable mycobacterial aerosols. 17 Together, these results suggest that the MTB/RIF test can be done without special biosafety precautions.
Our study fi ndings have several limitations. The use of diff erent study designs and diagnostic algorithms across sites made a direct comparison of fi ndings challenging. Our study did not allow us to determine the eff ect of rapid and early detection on the number of patients treated and on treatment outcomes, as longterm follow-up was not undertaken and as the parallel use of culture, not otherwise routinely available, may have aff ected physicians' choices. Additionally, the study did not include any testing of close contacts to measure eff ect on transmission. Participating sites were urban or periurban and supply chain manage ment, reagent storage, and calibration are likely to be more problematic in rural areas.
Overall, our fi ndings suggest that decentralised MTB/RIF test implementation is feasible and could lead to an improvement in tuberculosis care and control. Any improvement will require increased detection of tuberculosis and multidrug-resistant-tuberculosis to coincide with scale-up of fi rst-line, and more importantly, second-line treatment. 42 Whether early and appropriate treatment after MTB/RIF testing can reduce tuberculosisassociated morbidity and mortality, and its eff ect on transmission, needs to be established.
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